Novo Nordisk A/S (NYSE:NVO) Sets New 1-Year Low – Should You Sell?

Novo Nordisk A/S (NYSE:NVO) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $35.14 and last traded at $35.4710, with a volume of 474729 shares. The stock had previously closed at $36.04.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on NVO shares. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. HSBC reiterated a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

The stock has a market capitalization of $158.23 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 8.52 and a beta of 0.73. The stock’s 50 day moving average is $45.92 and its two-hundred day moving average is $50.42. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a yield of 718.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 52.74%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently modified their holdings of the stock. True Wealth Design LLC grew its holdings in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S in the third quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at $25,000. WealthCollab LLC boosted its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the period. Finally, American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $28,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.